Kangmei Pharmaceutical Co., Ltd.

SHSE:600518 Stock Report

Market Cap: CN¥36.3b

Kangmei Pharmaceutical Past Earnings Performance

Past criteria checks 2/6

Kangmei Pharmaceutical has been growing earnings at an average annual rate of 33.8%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 16.3% per year. Kangmei Pharmaceutical's return on equity is 3.6%, and it has net margins of 4.9%.

Key information

33.8%

Earnings growth rate

43.9%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-16.3%
Return on equity3.6%
Net Margin4.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

We Think Kangmei Pharmaceutical's (SHSE:600518) Robust Earnings Are Conservative

Nov 06
We Think Kangmei Pharmaceutical's (SHSE:600518) Robust Earnings Are Conservative

Kangmei Pharmaceutical's (SHSE:600518) Performance Is Even Better Than Its Earnings Suggest

May 06
Kangmei Pharmaceutical's (SHSE:600518) Performance Is Even Better Than Its Earnings Suggest

Recent updates

Subdued Growth No Barrier To Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) With Shares Advancing 35%

Nov 08
Subdued Growth No Barrier To Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) With Shares Advancing 35%

We Think Kangmei Pharmaceutical's (SHSE:600518) Robust Earnings Are Conservative

Nov 06
We Think Kangmei Pharmaceutical's (SHSE:600518) Robust Earnings Are Conservative

Is Kangmei Pharmaceutical (SHSE:600518) A Risky Investment?

Oct 28
Is Kangmei Pharmaceutical (SHSE:600518) A Risky Investment?

What Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) P/S Is Not Telling You

Aug 03
What Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) P/S Is Not Telling You

We Think Kangmei Pharmaceutical (SHSE:600518) Can Stay On Top Of Its Debt

Jun 17
We Think Kangmei Pharmaceutical (SHSE:600518) Can Stay On Top Of Its Debt

Kangmei Pharmaceutical's (SHSE:600518) Performance Is Even Better Than Its Earnings Suggest

May 06
Kangmei Pharmaceutical's (SHSE:600518) Performance Is Even Better Than Its Earnings Suggest

Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) Price Is Out Of Tune With Revenues

Apr 10
Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) Price Is Out Of Tune With Revenues

Revenue & Expenses Breakdown

How Kangmei Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SHSE:600518 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 245,21325665440
30 Jun 244,97124463045
31 Mar 244,93116075546
31 Dec 234,87410377746
30 Sep 234,992-1,9501,24144
30 Jun 234,778-2,6181,29537
31 Mar 234,390-2,6271,22831
31 Dec 224,180-2,6881,25125
30 Sep 223,7888,0572,32217
30 Jun 223,8628,6522,36613
31 Mar 223,9998,4022,4099
31 Dec 214,1537,9182,4759
30 Sep 214,526-29,7382,642-25
30 Jun 214,965-30,5912,742-10
31 Mar 215,330-31,3833,0951
31 Dec 205,412-31,0853,02411
30 Sep 205,070-7,2901,60489
30 Jun 205,830-6,3951,88792
31 Mar 207,714-5,2481,902103
31 Dec 1911,446-4,8862,324110
30 Sep 1912,918-2812,703109
30 Jun 1915,590-292,720127
31 Mar 1919,3659422,501129
31 Dec 1817,0653742,578142
30 Sep 1812,559-3123,064153
30 Jun 1813,9244872,753205
31 Mar 1815,3171,3412,599170
31 Dec 1717,5792,1502,478141
30 Sep 1724,7013,9001,81891
30 Jun 1723,7013,7261,8160
31 Mar 1722,9113,4191,7010
31 Dec 1621,6423,3401,6040
30 Sep 1621,0673,2411,4670
30 Jun 1620,2053,0901,3890
31 Mar 1618,9502,9281,2940
31 Dec 1518,0672,7571,2540
30 Sep 1517,8272,8951,1220
30 Jun 1517,2522,6921,0850
31 Mar 1516,7552,5131,0230
31 Dec 1415,9492,2869680
30 Sep 1415,4591,9919640
30 Jun 1415,0151,9629430
31 Mar 1414,2331,9139150
31 Dec 1313,3591,8808620

Quality Earnings: 600518 has a large one-off loss of CN¥69.5M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 600518 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 600518 has become profitable over the past 5 years, growing earnings by 33.8% per year.

Accelerating Growth: 600518 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 600518 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).

Return on Equity

High ROE: 600518's Return on Equity (3.6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 09:50
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kangmei Pharmaceutical Co., Ltd. is covered by 17 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuchang LiuChangjiang Securities Co. LTD.
Pei Hui TangChasing Securities
Peng ZouChina International Capital Corporation Limited